Literature DB >> 9442462

Trace elements and chronic liver diseases.

C Loguercio1, V De Girolamo, A Federico, S L Feng, V Cataldi, C Del Vecchio Blanco, G Gialanella.   

Abstract

The relationships between chronic liver diseases and trace element (TE) contents are debated. Particularly, no defined data are available about the TE levels in viral liver disease patients with or without malnutrition. In this study we evaluated blood and plasma levels of various trace elements in patients with HCV-related chronic liver disease, at different stages of liver damage (8 patients with chronic hepatitis and 32 with liver cirrhosis) with or without malnutrition. We also studied 10 healthy volunteers as control group. We found that cirrhotic subjects had a significant decrease of blood levels of Zn and Se, independently on the nutritional status, whereas plasma levels of Fe were significantly reduced only in malnourished cirrhotic patients. Our data indicate that liver impairment is the main cause of the blood decrease of Se and Zn levels in patients with non alcoholic liver disease, whereas the malnutrition affects Fe levels only.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9442462     DOI: 10.1016/s0946-672x(97)80045-4

Source DB:  PubMed          Journal:  J Trace Elem Med Biol        ISSN: 0946-672X            Impact factor:   3.849


  16 in total

1.  Randomized controlled trial of consensus interferon with or without zinc for chronic hepatitis C patients with genotype 2.

Authors:  Hideyuki Suzuki; Ken Sato; Hitoshi Takagi; Daisuke Kanda; Naondo Sohara; Satoru Kakizaki; Hiroaki Nakajima; Toshiyuki Otsuka; Takeaki Nagamine; Masatomo Mori
Journal:  World J Gastroenterol       Date:  2006-02-14       Impact factor: 5.742

Review 2.  Reprint of: Nutrition in the Management of Cirrhosis and its Neurological Complications.

Authors:  Chantal Bémeur; Roger F Butterworth
Journal:  J Clin Exp Hepatol       Date:  2015-02-19

3.  Alcohol-induced myocardial fibrosis in metallothionein-null mice: prevention by zinc supplementation.

Authors:  Lipeng Wang; Zhanxiang Zhou; Jack T Saari; Y James Kang
Journal:  Am J Pathol       Date:  2005-08       Impact factor: 4.307

Review 4.  Nutrition in the management of cirrhosis and its neurological complications.

Authors:  Chantal Bémeur; Roger F Butterworth
Journal:  J Clin Exp Hepatol       Date:  2013-06-11

Review 5.  The use of selected nutrition supplements and complementary and alternative medicine in liver disease.

Authors:  A James Hanje; Brett Fortune; Ming Song; Daniell Hill; Craig McClain
Journal:  Nutr Clin Pract       Date:  2006-06       Impact factor: 3.080

6.  Blood micronutrient, oxidative stress, and viral load in patients with chronic hepatitis C.

Authors:  Wang-Sheng Ko; Chih-Hung Guo; Maw-Sheng Yeh; Li-Yun Lin; Guoo-Shyng W Hsu; Pei-Chung Chen; Mei-Ching Luo; Chia-Yeh Lin
Journal:  World J Gastroenterol       Date:  2005-08-14       Impact factor: 5.742

7.  Blood cell, liver function, and response changes by PEG-interferon-alpha2b plus ribavirin with polaprezinc therapy in patients with chronic hepatitis C.

Authors:  Ke Ih Kim; Soo Ryang Kim; Noriko Sasase; Yoko Akimoto; Mao Shikata; Aya Ohtani; Teruko Hirooka; Kazuhiko Tanaka
Journal:  Hepatol Int       Date:  2008-01-11       Impact factor: 6.047

Review 8.  Can zinc enhance response interferon therapy for patients with HCV-related liver disease?

Authors:  Toru Ishikawa
Journal:  World J Gastroenterol       Date:  2012-07-07       Impact factor: 5.742

9.  A possible predictive marker of progression for hepatocellular carcinoma.

Authors:  Michele DI Stasio; Maria Grazia Volpe; Giovanni Colonna; Melissa Nazzaro; Miriam Polimeno; Stefania Scala; Giuseppe Castello; Susan Costantini
Journal:  Oncol Lett       Date:  2011-08-09       Impact factor: 2.967

10.  Triple therapy of interferon and ribavirin with zinc supplementation for patients with chronic hepatitis C: a randomized controlled clinical trial.

Authors:  Hideyuki Suzuki; Hitoshi Takagi; Naondo Sohara; Daisuke Kanda; Satoru Kakizaki; Ken Sato; Masatomo Mori
Journal:  World J Gastroenterol       Date:  2006-02-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.